Search Results - "GEE, Julia"

Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival by LAW, Jennifer H, HABIBI, Golareh, NICHOLSON, Robert I, CARBONI, Joan, GOTTARDIS, Marco, POLLAK, Michael, DUNN, Sandra E, KAIJI HU, MASOUDI, Hamid, WANG, Michelle Y. C, STRATFORD, Anna L, PARK, Eugene, GEE, Julia M. W, FINLAY, Pauline, JONES, Helen E

“…Drugs that target the insulin-like growth factor-I receptor (IGF-IR) and/or insulin receptor (IR) are currently under investigation for a variety of…”
Get full text

Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer by Achinger-Kawecka, Joanna, Valdes-Mora, Fatima, Luu, Phuc-Loi, Giles, Katherine A., Caldon, C. Elizabeth, Qu, Wenjia, Nair, Shalima, Soto, Sebastian, Locke, Warwick J., Yeo-Teh, Nicole S., Gould, Cathryn M., Du, Qian, Smith, Grady C., Ramos, Irene R., Fernandez, Kristine F., Hoon, Dave S., Gee, Julia M. W., Stirzaker, Clare, Clark, Susan J.

“…Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, but the underlying molecular mechanisms are largely…”
Get full text

Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen by Habashy, Hany Onsy, Powe, Desmond G, Staka, Cindy M, Rakha, Emad A, Ball, Graham, Green, Andrew R, Aleskandarany, Mohammed, Paish, E. Claire, Douglas Macmillan, R, Nicholson, Robert I, Ellis, Ian O, Gee, Julia M. W

“…Transferrin receptor (CD71) is involved in the cellular uptake of iron and is expressed on cells with high proliferation. It may be implicated in promoting the…”
Get full text

The ZIP6/ZIP10 heteromer is essential for the zinc-mediated trigger of mitosis by Nimmanon, Thirayost, Ziliotto, Silvia, Ogle, Olivia, Burt, Anna, Gee, Julia M. W., Andrews, Glen K., Kille, Pete, Hogstrand, Christer, Maret, Wolfgang, Taylor, Kathryn M.

“…Zinc has been known to be essential for cell division for over 40 years but the molecular pathways involved remain elusive. Cellular zinc import across…”
Get full text

Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study by Kuter, Irene, Gee, Julia M. W., Hegg, Roberto, Singer, Christian F., Badwe, Rajendra A., Lowe, Elizabeth S., Emeribe, Ugochi A., Anderson, Elizabeth, Sapunar, Francisco, Finlay, Pauline, Nicholson, Robert I., Bines, José, Harbeck, Nadia

“…NEWEST (Neoadjuvant Endocrine Therapy for Women with Estrogen-Sensitive Tumors) is the first study to compare biological and clinical activity of fulvestrant…”
Get full text

MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer by Milevskiy, Michael J. G., Gujral, Udai, Del Lama Marques, Carolina, Stone, Andrew, Northwood, Korinne, Burke, Lez J., Gee, Julia M. W., Nephew, Kenneth, Clark, Susan, Brown, Melissa A.

“…Background MicroRNAs are potent post-transcriptional regulators involved in all hallmarks of cancer. Mir-196a is transcribed from two loci and has been…”
Get full text

The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer by Achinger-Kawecka, Joanna, Stirzaker, Clare, Portman, Neil, Campbell, Elyssa, Chia, Kee-Ming, Du, Qian, Laven-Law, Geraldine, Nair, Shalima S., Yong, Aliza, Wilkinson, Ashleigh, Clifton, Samuel, Milioli, Heloisa H., Alexandrou, Sarah, Caldon, C. Elizabeth, Song, Jenny, Khoury, Amanda, Meyer, Braydon, Chen, Wenhan, Pidsley, Ruth, Qu, Wenjia, Gee, Julia M. W., Schmitt, Anthony, Wong, Emily S., Hickey, Theresa E., Lim, Elgene, Clark, Susan J.

“…Three-dimensional (3D) epigenome remodeling is an important mechanism of gene deregulation in cancer. However, its potential as a target to counteract therapy…”
Get full text

DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer by Stone, Andrew, Zotenko, Elena, Locke, Warwick J., Korbie, Darren, Millar, Ewan K. A., Pidsley, Ruth, Stirzaker, Clare, Graham, Peter, Trau, Matt, Musgrove, Elizabeth A., Nicholson, Robert I., Gee, Julia M. W., Clark, Susan J.

“…Expression of oestrogen receptor (ESR1) determines whether a breast cancer patient receives endocrine therapy, but does not guarantee patient response. The…”
Get full text

Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro by Jordan, Nicola J, Dutkowski, Carol M, Barrow, Denise, Mottram, Huw J, Hutcheson, Iain R, Nicholson, Robert I, Guichard, Sylvie M, Gee, Julia M W

“…Upregulation of PI3K/Akt/mTOR signalling in endocrine-resistant breast cancer (BC) has identified mTOR as an attractive target alongside anti-hormones to…”
Get full text

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer by Eccles, Suzanne A, Aboagye, Eric O, Ali, Simak, Anderson, Annie S, Armes, Jo, Berditchevski, Fedor, Blaydes, Jeremy P, Brennan, Keith, Brown, Nicola J, Bryant, Helen E, Bundred, Nigel J, Burchell, Joy M, Campbell, Anna M, Carroll, Jason S, Clarke, Robert B, Coles, Charlotte E, Cook, Gary J R, Cox, Angela, Curtin, Nicola J, Dekker, Lodewijk V, Silva, Isabel dos Santos, Duffy, Stephen W, Easton, Douglas F, Eccles, Diana M, Edwards, Dylan R, Edwards, Joanne, Evans, D, Fenlon, Deborah F, Flanagan, James M, Foster, Claire, Gallagher, William M, Garcia-Closas, Montserrat, Gee, Julia M W, Gescher, Andy J, Goh, Vicky, Groves, Ashley M, Harvey, Amanda J, Harvie, Michelle, Hennessy, Bryan T, Hiscox, Stephen, Holen, Ingunn, Howell, Sacha J, Howell, Anthony, Hubbard, Gill, Hulbert-Williams, Nick, Hunter, Myra S, Jasani, Bharat, Jones, Louise J, Key, Timothy J, Kirwan, Cliona C, Kong, Anthony, Kunkler, Ian H, Langdon, Simon P, Leach, Martin O, Mann, David J, Marshall, John F, Martin, Lesley, Martin, Stewart G, Macdougall, Jennifer E, Miles, David W, Miller, William R, Morris, Joanna R, Moss, Sue M, Mullan, Paul, Natrajan, Rachel, O'Connor, James P B, O'Connor, Rosemary, Palmieri, Carlo, Pharoah, Paul D P, Rakha, Emad A, Reed, Elizabeth, Robinson, Simon P, Sahai, Erik, Saxton, John M, Schmid, Peter, Smalley, Matthew J, Speirs, Valerie, Stein, Robert, Stingl, John, Streuli, Charles H, Tutt, Andrew N J, Velikova, Galina, Walker, Rosemary A, Watson, Christine J, Williams, Kaye J, Young, Leonie S, Thompson, Alastair M

“…Breast cancer remains a significant scientific, clinical and societal challenge. This gap analysis has reviewed and critically assessed enduring issues and new…”
Get full text

ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer by Kalyuga, Maria, Gallego-Ortega, David, Lee, Heather J, Roden, Daniel L, Cowley, Mark J, Caldon, C Elizabeth, Stone, Andrew, Allerdice, Stephanie L, Valdes-Mora, Fatima, Launchbury, Rosalind, Statham, Aaron L, Armstrong, Nicola, Alles, M Chehani, Young, Adelaide, Egger, Andrea, Au, Wendy, Piggin, Catherine L, Evans, Cara J, Ledger, Anita, Brummer, Tilman, Oakes, Samantha R, Kaplan, Warren, Gee, Julia M W, Nicholson, Robert I, Sutherland, Robert L, Swarbrick, Alexander, Naylor, Matthew J, Clark, Susan J, Carroll, Jason S, Ormandy, Christopher J

“…We have previously shown that during pregnancy the E-twenty-six (ETS) transcription factor ELF5 directs the differentiation of mammary progenitor cells toward…”
Get full text

Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer by Stone, Andrew, Valdés-Mora, Fatima, Gee, Julia M W, Farrow, Lynne, McClelland, Richard A, Fiegl, Heidi, Dutkowski, Carol, McCloy, Rachael A, Sutherland, Robert L, Musgrove, Elizabeth A, Nicholson, Robert I

“…In the present study, we have taken the novel approach of using an in vitro model representative of tamoxifen-withdrawal subsequent to clinical relapse to…”
Get full text

Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer by Ziliotto, Silvia, Gee, Julia M. W, Ellis, Ian O, Green, Andrew R, Finlay, Pauline, Gobbato, Anna, Taylor, Kathryn M

“…ZIP7, a member of the ZIP family of zinc importers, resides on the endoplasmic reticulum membrane and transports zinc from intracellular stores to the…”
Get full text

ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells by Gallego-Ortega, David, Ledger, Anita, Roden, Daniel L, Law, Andrew M K, Magenau, Astrid, Kikhtyak, Zoya, Cho, Christina, Allerdice, Stephanie L, Lee, Heather J, Valdes-Mora, Fatima, Herrmann, David, Salomon, Robert, Young, Adelaide I J, Lee, Brian Y, Sergio, C Marcelo, Kaplan, Warren, Piggin, Catherine, Conway, James R W, Rabinovich, Brian, Millar, Ewan K A, Oakes, Samantha R, Chtanova, Tatyana, Swarbrick, Alexander, Naylor, Matthew J, O'Toole, Sandra, Green, Andrew R, Timpson, Paul, Gee, Julia M W, Ellis, Ian O, Clark, Susan J, Ormandy, Christopher J

“…During pregnancy, the ETS transcription factor ELF5 establishes the milk-secreting alveolar cell lineage by driving a cell fate decision of the mammary luminal…”
Get full text

Smart Compression Sock for Early Detection of Diabetic Foot Ulcers by Billings, Julia, Gee, Julia, Ghulam, Zinah, Abdullah, Hussein A

“…The prevention of diabetic foot ulcers remains a critical challenge. This study evaluates a smart compression sock designed to address this issue by…”
Get full text

Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long‐term effects based on sequential biopsies by Agrawal, Amit, Robertson, John F.R., Cheung, Kwok L., Gutteridge, Eleanor, Ellis, Ian O., Nicholson, Robert I., Gee, Julia M.W.

“…We report the first study of the biological effect of fulvestrant on ER positive clinical breast cancer using sequential biopsies through to progression…”
Get full text

Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER + Invasive Breast Cancer (STAKT) by Robertson, John F R, Coleman, Robert E, Cheung, Kwok-Leung, Evans, Abigail, Holcombe, Chris, Skene, Anthony, Rea, Daniel, Ahmed, Samreen, Jahan, Ali, Horgan, Kieran, Rauchhaus, Petra, Littleford, Roberta, Cheung, S Y Amy, Cullberg, Marie, de Bruin, Elza C, Koulai, Loumpiana, Lindemann, Justin P O, Pass, Martin, Rugman, Paul, Schiavon, Gaia, Deb, Rahul, Finlay, Pauline, Foxley, Andrew, Gee, Julia M W

“…The STAKT study examined short-term exposure (4.5 days) to the oral selective pan-AKT inhibitor capivasertib (AZD5363) to determine if this drug can reach its…”
Get full text

Long-range regulators of the lncRNA HOTAIR enhance its prognostic potential in breast cancer by Milevskiy, Michael J G, Al-Ejeh, Fares, Saunus, Jodi M, Northwood, Korinne S, Bailey, Peter J, Betts, Joshua A, McCart Reed, Amy E, Nephew, Kenneth P, Stone, Andrew, Gee, Julia M W, Dowhan, Dennis H, Dray, Eloise, Shewan, Annette M, French, Juliet D, Edwards, Stacey L, Clark, Susan J, Lakhani, Sunil R, Brown, Melissa A

“…Predicting response to endocrine therapy and survival in oestrogen receptor positive breast cancer is a significant clinical challenge and novel prognostic…”
Get full text

A Good Drug Made Better: The Fulvestrant Dose-Response Story by Robertson, John F.R, Lindemann, Justin, Garnett, Sally, Anderson, Elizabeth, Nicholson, Robert I, Kuter, Irene, Gee, Julia M.W

“…Abstract Sequential use of endocrine therapies remains the cornerstone of treatment for hormone receptor-positive advanced breast cancer, before the use of…”
Get full text

Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells by Knowlden, Janice M, Hutcheson, Iain R, Jones, Helen E, Madden, Tracieann, Gee, Julia M. W, Harper, Maureen E, Barrow, Denise, Wakeling, Alan E, Nicholson, Robert I

“…The development of acquired resistance to antihormonal agents in breast cancer is a major therapeutic problem. We have developed a tamoxifen-resistant (TAM-R)…”
Get full text